• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人乳头瘤病毒疫苗的适应症与疗效。

Indications and efficacy of the human papillomavirus vaccine.

作者信息

Hakim Amy A, Lin Paul S, Wilczynski Sharon, Nguyen Kimhuynh, Lynes Billie, Wakabayashi Mark T

机构信息

Department of Gynecologic Oncology, City of Hope, 1500 East Duarte Road, Duarte, CA 91010-3000, USA.

出版信息

Curr Treat Options Oncol. 2007 Dec;8(6):393-401. doi: 10.1007/s11864-007-0050-0.

DOI:10.1007/s11864-007-0050-0
PMID:18172770
Abstract

In the United States, there are 11,150 cases and 3670 deaths projected due to invasive cervical cancer for 2007. Approximately 500,000 new cases and 274,000 deaths will occur in women throughout the world. Human papillomavirus (HPV) has been designated by the World Health Organization (WHO) as a "necessary cause" of cervical cancer. There are 6.2 million new cases of HPV diagnosed each year. In addition to cervical cancer, the virus has also been implicated in vaginal, vulvar, penile, anal, and head and neck cancers. Current methods for prevention of cervical cancer include Pap smears, HPV testing, ablative procedures, cervical conization, and hysterectomy. These are costly as well as invasive. The HPV vaccine is the most recent breakthrough for the prevention of cervical cancer. The quadrivalent HPV vaccine (Gardasil) covers types 6, 11, 16, & 18. The bivalent vaccine (Cervarix) covers types 16 & 18, and is expected to come out in the early part of 2007. Approximately 70% of cervical cancer is caused by HPV types 16 & 18. HPV types 6 &11 are responsible for 90% of anogenital warts. Females of ages 11-12 and those prior to their sexual debut should be vaccinated, with all females in the age range of 9-26 also eligible. This vaccination strategy can prevent the above HPV infections, cervical dysplasia, and possibly cervical cancer.

摘要

在美国,预计2007年侵袭性宫颈癌病例有11150例,死亡3670例。全世界女性中约有50万新发病例,27.4万人死亡。人乳头瘤病毒(HPV)已被世界卫生组织(WHO)认定为宫颈癌的“必要病因”。每年有620万例HPV新诊断病例。除宫颈癌外,该病毒还与阴道癌、外阴癌、阴茎癌、肛门癌以及头颈癌有关。目前预防宫颈癌的方法包括巴氏涂片检查、HPV检测、消融手术、宫颈锥切术和子宫切除术。这些方法既昂贵又具有侵入性。HPV疫苗是预防宫颈癌的最新突破。四价HPV疫苗(佳达修)涵盖6、11、16和18型。二价疫苗(希瑞适)涵盖16和18型,并预计在2007年初上市。约70%的宫颈癌由16和18型HPV引起。6和11型HPV导致90%的肛门生殖器疣。11至12岁以及首次性行为前的女性应接种疫苗,9至26岁的所有女性也都符合接种条件。这种疫苗接种策略可以预防上述HPV感染、宫颈发育异常,并有可能预防宫颈癌。

相似文献

1
Indications and efficacy of the human papillomavirus vaccine.人乳头瘤病毒疫苗的适应症与疗效。
Curr Treat Options Oncol. 2007 Dec;8(6):393-401. doi: 10.1007/s11864-007-0050-0.
2
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗:免疫实践咨询委员会(ACIP)的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
3
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.四价人乳头瘤病毒(6/11/16/18型)疫苗对高级别宫颈和外生殖器病变持续预防效果的汇总分析。
Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.
4
Quadrivalent human papillomavirus vaccine.四价人乳头瘤病毒疫苗
Clin Infect Dis. 2007 Sep 1;45(5):609-7. doi: 10.1086/520654. Epub 2007 Jul 25.
5
Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.二价和四价人乳头瘤病毒疫苗在意大利的成本-效益评估:不同交叉保护谱的潜在影响。
Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19.
6
Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.马来西亚宫颈癌相关疾病负担以及人乳头瘤病毒(HPV)疫苗接种的潜在成本与后果
Asian Pac J Cancer Prev. 2010;11(6):1551-9.
7
Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...用于6、11、16和18型的人乳头瘤病毒疫苗:新药。预防宫颈癌:寄予厚望……
Prescrire Int. 2007 Jun;16(89):91-4.
8
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.美国对癌症中HPV类型的评估:对当前和九价HPV疫苗的影响。
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086. doi: 10.1093/jnci/djv086. Print 2015 Jun.
9
Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.参与国际四价人乳头瘤病毒(6/11/16/18型)疫苗临床试验的受试者的基线人口统计学特征。
Curr Med Res Opin. 2008 Jun;24(6):1623-34. doi: 10.1185/03007990802068151. Epub 2008 Apr 23.
10
[Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].[人乳头瘤病毒疫苗接种。宫颈癌防控中的实施与效果]
Bull Acad Natl Med. 2007 Dec;191(9):1805-16; discussion 1816-7.

引用本文的文献

1
Embryonic stem cell-specific signature in cervical cancer.宫颈癌中的胚胎干细胞特异性特征
Tumour Biol. 2014 Mar;35(3):1727-38. doi: 10.1007/s13277-013-1321-y. Epub 2013 Oct 28.
2
Prevalence of high-risk human papilloma virus among women with hepatitis C virus before liver transplantation.肝移植前丙型肝炎病毒感染女性中高危型人乳头瘤病毒的流行情况
Transpl Infect Dis. 2013 Aug;15(4):400-4. doi: 10.1111/tid.12086. Epub 2013 May 6.
3
Male genital premalignant dermatoses.男性生殖器癌前皮肤病。

本文引用的文献

1
Human papillomaviruses in head and neck carcinomas.头颈部癌中的人乳头瘤病毒
N Engl J Med. 2007 May 10;356(19):1993-5. doi: 10.1056/NEJMe078004.
2
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.预防肛门生殖器疾病的四价人乳头瘤病毒疫苗。
N Engl J Med. 2007 May 10;356(19):1928-43. doi: 10.1056/NEJMoa061760.
3
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.预防高级别宫颈病变的四价人乳头瘤病毒疫苗。
Curr Urol Rep. 2012 Dec;13(6):488-95. doi: 10.1007/s11934-012-0284-7.
4
CCDB: a curated database of genes involved in cervix cancer.CCDB:一个精心策划的宫颈癌相关基因数据库。
Nucleic Acids Res. 2011 Jan;39(Database issue):D975-9. doi: 10.1093/nar/gkq1024. Epub 2010 Nov 2.
N Engl J Med. 2007 May 10;356(19):1915-27. doi: 10.1056/NEJMoa061741.
4
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗:免疫实践咨询委员会(ACIP)的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
5
Parental response to the introduction of a vaccine against human papilloma virus.父母对引入人乳头瘤病毒疫苗的反应。
Hum Vaccin. 2006 Nov-Dec;2(6):243-8. doi: 10.4161/hv.2.6.3391. Epub 2006 Nov 12.
6
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.预防性四价人乳头瘤病毒(6、11、16和18型)L1病毒样颗粒疫苗在男性和女性青少年及年轻成年女性中的免疫原性和反应原性比较。
Pediatrics. 2006 Nov;118(5):2135-45. doi: 10.1542/peds.2006-0461.
7
ACOG Committee Opinion No. 344: Human papillomavirus vaccination.美国妇产科医师学会第344号委员会意见:人乳头瘤病毒疫苗接种
Obstet Gynecol. 2006 Sep;108(3 Pt 1):699-705. doi: 10.1097/00006250-200609000-00047.
8
Who should be vaccinated against human papillomavirus?哪些人应该接种人乳头瘤病毒疫苗?
Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1498-9. doi: 10.1111/j.1525-1438.2006.00620.x.
9
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.二价L1病毒样颗粒疫苗针对16型和18型人乳头瘤病毒长达4.5年的持续疗效:一项随机对照试验的随访结果
Lancet. 2006 Apr 15;367(9518):1247-55. doi: 10.1016/S0140-6736(06)68439-0.
10
Advances in prevention of cervical cancer and other human papillomavirus-related diseases.宫颈癌及其他与人乳头瘤病毒相关疾病的预防进展
Pediatr Infect Dis J. 2006 Feb;25(2 Suppl):S65-81, quiz S82. doi: 10.1097/01.inf.0000196485.86376.46.